Life of equal pay advocate Lilly Ledbetter portrayed in film
An exclusive screening of the film drew Jacksonville State University students and the community to the Stone Center Theatre on Thursday.
Ledbetter, who died in October 2024, was the first woman to work in a management position at a Good Year Tire Plant starting in 1979. Ledbetter spent nearly 19 years working at the plant, making significantly less than her male colleagues.
US citizen held by ICE despite judge seeing birth certificate
After filing a lawsuit, and facing several setbacks, her case reached the U.S Supreme Court where she ultimately lost.
Despite this, Ledbetter persevered and former President Barack Obama signed the Lilly Ledbetter Fair Pay Act into legislation in 2009.
Some who attended Thursday's screening said Ledbetter's fight is inspiring to see on the big screen.
'It's very inspiring to see someone who grew up on Possum Trot Road take their case all the way to the Supreme Court and then beyond, with congress and President Obama's Fair Pay Act. So we're very excited, again to celebrate that legacy that didn't just impact our community, it impacted the nation,' said Rock Executive Director at the Randy Owen's Center Emily Duncan.
The film is set to be released on May 9.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
a day ago
- Business Insider
Analysts Rally Behind Eli Lilly (LLY) Stock After 24% Slide
Over the past year, Eli Lilly (LLY) stock has tumbled almost 24%, pressured by regulatory concerns, disappointing trial results, and broader market volatility. Yet beneath the selloff, Lilly's fundamentals remain strong, with recent results underscoring the company's resilience. Following this pullback, the stock's valuation looks increasingly attractive relative to its medium-term growth potential—suggesting a potential opportunity for long-term value investors. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. I remain Bullish on LLY stock with recent declines toward $700 serving as a decent opportunity to establish a long-term position. Why the Pressure on Lilly's Stock? To be fair, the recent slide in Eli Lilly's stock isn't just a random blip. Investors are spooked by a few things. First, there's the regulatory cloud hanging over the pharma industry as a whole due to President Trump's push for lower drug prices, including his 'most favored nation' policy to tie U.S. drug costs to cheaper international prices, which has folks worried about profit margins. Lilly's CEO, Dave Ricks, even called out the U.S. system's inefficiencies, like high consumer costs and red tape, which could get messier with new policies. Then there's the disappointment from the orforglipron trial; Lilly's experimental obesity pill showed an average weight loss of 12.4%, solid but below Wall Street's lofty estimates, sparking another subsequent sell-off on Aug. 7th. Add in broader market volatility, and it's no wonder investors are hitting the sell button. Discussions among investors are centering on whether Lilly's blockbuster drugs, Mounjaro and Zepbound, can sustain their momentum. The incretin market, where these drugs dominate, is getting crowded, and there's chatter about potential supply chain hiccups or market saturation. Nonetheless, these concerns might be overshadowing the bigger picture. Eli Lilly is Still a Rocketship Despite the gloom, Lilly's Q2 earnings crushed market expectations. On August 7th, the pharma giant posted revenue of $15.56 billion, up 38% year-over-year, blowing past Wall Street's $14.71 billion estimate. Earnings per share hit $6.31, a 61% jump from last year, beating forecasts by 12.48%. Mounjaro and Zepbound once again stole the spotlight, with Mounjaro raking in $5.2 billion (up 68%), while Zepbound brought in $3.38 billion (up 172%). These drugs are fueling Lilly's dominance in the diabetes and weight loss markets, with Mounjaro even snagging the top spot in U.S. prescriptions for type 2 diabetes incretins. Other highlights included Lilly's gross margin, which rose to 85%, up 3 points, thanks to better production costs and a favorable product mix. Then you have management investing heavily, with R&D expenses up 23% to $3.34 billion. I think this clearly shows confidence in Lilly's pipeline, and judging by the superb returns on invested capital the company has seen historically, I see this as great news. To top it all off, Lilly raised its full-year revenue guidance to $60–62 billion and EPS to $21.75–$23.00, reflecting strength across its portfolio, including some new launches like Kisunla and acquisitions like SiteOne Therapeutics for non-opioid pain treatments. As LLY CEO Dave Ricks put it in recent commentary to the market: 'Lilly is rolling,' and the numbers back that up. Is Eli Lilly a Hidden Gem? Eli Lilly's stock has always carried a premium, and for good reason. Growth rates have been off the charts, with its forward P/E ratio hovering between 40x and 60x in recent years. But following the recent 24% drop, things are looking different. At around $700 per share, Lilly stock is trading at about 30x this year's expected EPS of about $23. That's not exactly dirt-cheap, but for a company with a projected EPS growth rate of 32% annually over the next five years, it's starting to feel like a bargain. Compare that to the S&P 500's average P/E of around 25, which comes with much inferior EPS growth estimates, and Lilly's premium looks justified given its 30% expected growth trajectory. The company's 15% revenue CAGR over the past five years and 80%+ gross profit margin show fantastic scale dynamics, and the momentum has hardly slowed down. Sure, there's risk, including potential regulatory changes or trial setbacks that could sting, but the current price seems to bake in a lot of that worry already. If we compare LLY's performance against broader U.S. benchmarks like the S&P 500 (SPX), LLY is maintaining a premium despite suffering over the past twelve months. What is the 12-Month Forecast for LLY Stock? There are 22 analysts offering price targets on LLY stock through TipRanks, with an overwhelmingly bullish consensus. Today, the stock carries a Strong Buy consensus rating based on 17 Buy and five Hold ratings over the past three months. LLY's average stock price target of $924.42 suggests ~31% upside over the next twelve months. LLY's Pullback is an Opportunity, Not a Trap Lilly's selloff looks more like an overreaction than a reflection of its true strength. Yes, regulatory noise, trial hiccups, and crowded competition have rattled investors, but the company's financial performance and growth runway remain hard to ignore. With Mounjaro and Zepbound fueling monster revenue gains, a strong pipeline, and raised guidance, Lilly still looks like one of the most potent growth stories in pharma. This is why, at current levels, I believe the stock feels less like a trap and more like an opportunity.
CNBC
2 days ago
- CNBC
Meta shares fall on AI restructuring report, while Lilly shrugs off Novo's Ozempic price move
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: Stocks aren't moving much Monday as Wall Street waits on retail earnings and a speech from Fed Chair Jay Powell later in the week. Monday's session lacks clear themes, but Meta Platforms stands out as a laggard after a report from The Information said the longtime Club holding is planning the fourth restructuring of its AI team in six months. The story is raising questions in light of Meta's significant investment in recruiting AI talent from other tech companies. Novo price cut : Shares of Club name Eli Lilly are relatively unchanged despite chief rival Novo Nordisk lowering prices for its popular GLP-1 medication. Novo Nordisk announced on Monday that it has cut the price of Ozempic, its popular GLP-1 for Type 2 diabetes, to $499 per month for cash-paying patients that use its NovoCare direct-to-patient program. Novo also announced that it has partnered with GoodRx to offer the same price for Ozempic and the weight-loss drug Wegovy at U.S. pharmacies. While the news may spark concerns that a price war is heating up in a battle for market share, we don't see this specific Ozempic development advancing that narrative. The main reason why is that the cash-pay market for GLP-1s to treat Type 2 diabetes is not as important as it is for their obesity counterparts. It all comes down to insurance coverage, which is much higher for these medications for diabetes than weight loss. Indeed, Lilly does not offer Type 2 diabetes treatment Mounjaro on its LillyDirect platform, while sister drug Zepbound for obesity is on there. Lilly executives were asked about this on the company's August earnings call, and the president of Lilly USA, Ilya Yuffa, had this to say: "With Mounjaro, we have significant coverage. So, over 90% coverage in both commercial as well as [Medicare] Part D. And so, we're not sure if [adding Mounjaro to LillyDirect] necessarily provides additional avenue. With Zepbound, we see significant growth because we do have coverage gaps in commercial. And obviously, we also have coverage gaps without having the ability to cover anti-obesity medications in Part D. So, we see this as an opportunity for us to meet that need. For what it's worth, we still like where Lilly sits in the obesity side of the GLP-1 market. Back in February, Eli Lilly announced that self-pay patients could get Zepbound single dose vials for $499 per month through its LillyDirect platform. That's on par with the price for Wegovy on NovoCare. Since head-to-head studies have found Lilly's Zepbound to be superior to Novo Nordisk's Wegovy on weight loss, patients should continue to prefer Lilly's GLP-1s. We initially downgraded our rating on Eli Lilly after its earnings a few weeks ago, partly due to concerns about a potential price war. However, we reversed course and upgraded the stock back to a buy-equivalent 1 following signs of confidence driven by significant insider buying activity. Nuclear win : Alphabet's Google and the nuclear energy company Kairos Power announced on Monday the deployment of an advanced nuclear plant to the grid. Per the agreement, a reactor operated by Kairos Power will deliver up to 50 megawatts of reliable, 24/7 energy to the Tennessee Valley Authority electric grid that powers Google data centers in Tennessee and Alabama. The electricity will come from Kairos' Hermes 2 plant, which is scheduled to begin operations in 2030. The collaboration underscores how hyperscalers are creating new partnerships with nuclear energy providers to secure, around-the-clock power supply toward the end of the decade. Unlike gas-fired electricity, nuclear power offers tech giants like Alphabet a way to run their data centers on clean energy while advancing their decarbonization goals. While Club name GE Vernova is probably best known for its heavy-duty gas turbines , the power generation company also makes small modular reactors that have gained in popularity, so nuclear developments are important to follow closely. Up next: Palo Alto Networks reports after the closing bell , the first of three Club stocks with earnings this week. Before the opening bell on Tuesday, we'll see earnings from Club name Home Depot , Medtronic , and Viking Holdings . On the data side, we'll see July housing starts and building permits, but we'll take are cue on the housing sector from what Home Depot management says on the earnings call. (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Business of Fashion
2 days ago
- Business of Fashion
GLP-1 Pills Will Be Priced Similarly to Injections, Wall Street Predicts
US prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with their weight-loss injections, analysts and investors say, in a departure from the usual practice of charging more for new medicines despite pressure to cut prices. Neither drugmaker has disclosed pricing plans for their new daily oral medications. With regulatory approvals and launches still months away, pricing plans could change. Denmark-based Novo expects approval later this year and to launch soon after, while Indianapolis-based Lilly expects to launch by August 2026. Novo's Wegovy and Lilly's Zepbound, administered as weekly injections, are the only highly effective weight-loss drugs targeting the GLP-1 hormone, and the United States is their biggest market. US list prices are about $1,000 per month or more, with both companies offering a monthly supply for $499 to customers paying cash rather than using health insurance. Both companies have said they developed oral weight-loss drugs to meet patient needs and widen access to the market, mindful that some people are averse to injections. ADVERTISEMENT The pills, however, are not more effective than the injections. Lilly said this month its pill orforglipron cut weight by 12.4 percent after 72 weeks in a trial. That compares with weight loss of 15 percent for Novo's daily oral semaglutide. Both trail Lilly's injection at up to 21 percent. UBS analyst Trung Huynh said that will cap Lilly's pricing. The price is 'probably going to come on par with the current drugs today or slightly lower,' Huynh said. TD Cowen analyst Michael Nedelcovych said he expects Novo's pill to debut near Wegovy's price, citing the precedent of its diabetes pill Rybelsus being priced at parity with injection Ozempic, the diabetes-treatment version of Wegovy. Novo executives told analysts this month they were not in a hurry for discount pricing for the new pill. Oral GLP-1 drugs will fill a niche rather than displace injections, according to analysts. TD Cowen estimates that pills will account for a percentage share of the global obesity drug market in the mid-teens by 2030, which could reach $150 billion by then. Growing Cash Pay US doctors, patients and insurers are pressing for lower prices to make the weight-loss drugs more affordable for the 40 percent of Americans who are obese. Typically, drugmakers launch new drugs at higher prices, citing scientific advances. President Donald Trump and lawmakers from both parties have urged the companies to reduce US prices. Novo declined to comment on pricing, pointing to Aug. 6 comments by David Moore, its US operations head, saying that the company may tap customers paying cash directly via its new NovoCare pharmacy, which was launched this year to sell Wegovy outside of insurance. A Lilly spokesperson called it premature to comment on pricing and launch plans for its pill because the company has not yet submitted data for regulatory approval. Peak annual sales forecasts for Lilly's orforglipron fell to as low as $10 billion after its trial data from earlier estimates of up to $30 billion, according to a Reuters review of analyst estimates. HSBC forecasts $15 billion in peak annual sales for Novo's pill, while Barclays expects only $1 billion. ADVERTISEMENT Manufacturing Volume A key question is how much supply will be available at the time of launch. Shortages of injectable GLP-1s in 2023 and 2024 opened the US market to cheaper compounded versions as the manufacturers failed to anticipate the huge demand. 'It's all about scale and pricing,' said Kevin Gade, portfolio manager at Bahl & Gaynor, which owns Lilly shares. Gade pointed to Novo's manufacturing challenge. The pill form requires about 75 times more active ingredient than the highest-dose Wegovy injection, two analysts told Reuters. Lilly has said it already has $808.5 million in orforglipron inventory for next year's expected launch. Novo has said it will launch its pill without supply constraints after billions of dollars in investment to expand semaglutide production. Despite the high production needs, Novo is unlikely to debut its pill at a higher price than Wegovy, said Karen Andersen, healthcare strategist at Morningstar. 'Particularly in the growing cash-pay market, I doubt it can risk a launch at a premium to Wegovy,' Andersen added. By Maggie Fick and Bhanvi Satija; Editors: Caroline Humer and Will Dunham Sign up to The Business of Beauty newsletter, your complimentary, must-read source for the day's most important beauty and wellness news and analysis.
